Dna Biomed Solns Stock Number Of Employees

DNA Stock  ILS 86.00  0.90  1.04%   
DNA Biomed Solns fundamentals help investors to digest information that contributes to DNA Biomed's financial success or failures. It also enables traders to predict the movement of DNA Stock. The fundamental analysis module provides a way to measure DNA Biomed's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to DNA Biomed stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

DNA Biomed Solns Company Number Of Employees Analysis

DNA Biomed's Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.

Number of Employees

 = 

Full Time

+

Part Time

More About Number Of Employees | All Equity Analysis

Current DNA Biomed Number Of Employees

    
  11  
Most of DNA Biomed's fundamental indicators, such as Number Of Employees, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, DNA Biomed Solns is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Employee typically refers to an individual working under a contract of employment, whether oral or written, express or implied, and has recognized his or her rights and duties. Most officers of corporations are included as employees and contractors are generally excluded.
Competition

Based on the recorded statements, DNA Biomed Solns is currently employing 11.0 people. This is 99.9% lower than that of the Electronic Equipment, Instruments & Components sector and 97.95% lower than that of the Information Technology industry. The number of employees for all Israel stocks is 99.94% higher than that of the company.

DNA Number Of Employees Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses DNA Biomed's direct or indirect competition against its Number Of Employees to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of DNA Biomed could also be used in its relative valuation, which is a method of valuing DNA Biomed by comparing valuation metrics of similar companies.
DNA Biomed is currently under evaluation in number of employees category among its peers.

DNA Fundamentals

About DNA Biomed Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze DNA Biomed Solns's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DNA Biomed using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DNA Biomed Solns based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in DNA Stock

DNA Biomed financial ratios help investors to determine whether DNA Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in DNA with respect to the benefits of owning DNA Biomed security.